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Abstract: A one-pot, two-step biocatalytic platform for the 
regiospecfic C-methylation and C-ethylation of aromatic substrates is 
described. The tandem process utilizes SalL (Salinospora tropica) 
for in situ synthesis of S-adenosyl-L-methionine, followed by 
alkylation of aromatic substrates using the C-methyltransferase 
NovO (Streptomyces spheroides). Application of this methodology is 
demonstrated by regiospecific methyl, ethyl and isotopically-labelled 
13CH3, 
13CD3 and CD3 groups from their corresponding SAM 
analogues formed in situ. 
Regiospecific, late-stage methylation is a powerful strategy 
for tuning the physical and biological properties of small 
molecules and biomacromolecules.[1] At present, synthetic 
methodologies that methylate C(sp2)-H bonds are predominantly 
limited to transition metal-catalyzed strategies, which require 
elevated temperatures and the need for additives such as 
ligands and oxidants.[2±4] In addition, these methodologies are 
typically regioselective rather than regiospecific, which further 
restricts their scope.[5,6] In contrast, Nature routinely employs S-
adenosyl-L-methionine (SAM) dependent methyltransferases 
(MTs) to methylate at O-, N-, S- and C- sites. Thus, MTs hold 
considerable potential for the development of a biocatalytic 
alkylation platform of small molecules.[7±9]  
Of the various MTs available, C-MTs are particularly 
attractive as they enable C-C bond formation under mild 
conditions relative to traditional Friedel-Crafts reactions.[10,11] 
One C-MT exemplar is NovO, which methylates the C-8 position 
of 1a in the biosynthesis of the antibiotic novobiocin to form 2a 
(Scheme 1a).[12] We and others have shown that regiospecific 
methylation of the 8-position of 1b is catalyzed by a novel His-
Arg motif, which facilitates the deprotonation of the phenolic 
proton in the 7-position, followed by methylation at position 8 by 
SAM to form 2b.[13,14] NovO is also effective in catalysing Friedel-
Crafts alkylations using non-natural SAM analogues to alkylate 
1b-d regiospecifically.[8,11] Furthermore, NovO accepts non-
natural substrates such as 3 to exclusively form 4 (Scheme 1b), 
which is currently only accessible by this process.[11]  
At present, the broader applicability of small-molecule MTs 
is hampered by the inherent instability of SAM (942 min at pH 8) 
as the corresponding methylating agent.[15,16]  Additionally, the 
synthesis of SAM by chemical methods results in the formation 
of a diastereomeric mixture, which increases the cost of the 
process and has the potential for undesirable C-MT inhibition by 
the unwanted diastereomer.[17,18] 
 
 
 
 
 
 
 
 
Scheme 1. Biocatalytic C-methylation of (a) coumarins (1a-d) and (b) 2,7-
dihydroxynaphthalene (3) catalysed by NovO. Both studies require the 
formation of SAM prior to C-methylation. (c) Development of a one-pot, two-
enzyme process involving in situ SAM formation (SalL) and C-methylation 
(NovO). SAM: S-adenosylmethionine. SAH: S-adenosylhomocysteine. 
A powerful strategy that overcomes the need to prepare 
and isolate SAM and SAM analogues would produce the 
cofactor in situ, followed by alkyl transfer.[19±23] The enzyme SalL 
(Salinospora tropica) is known to form SAM from ¶-deoxy-5-
chloroadenosine (ClDA, 5) and methionine (Met, 6).[24±28] As 
ClDA is readily prepared from adenosine in a one-pot process, 
the use of SalL offers an inexpensive and atom-efficient 
alternative to the use of methionine adenosyl transferases, 
which utilizes expensive ATP as the corresponding adenosyl 
donor and have been used previously for in situ SAM 
formation.[21,29±32]  
 At present, there have not been any reports on the utility of 
the SalL-catalysed SAM production in tandem with C-MTs in a 
one-pot procedure. Herein, we describe such a process for the 
methylation of small molecule aromatic scaffolds using SalL and 
the C-MT NovO (Scheme 1c). Additionally, we show that this 
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tandem strategy can be used to transfer ethyl groups and 
isotopically-labeled methyl groups.[33±35]  
 Initial investigations focused on determining the 
compatibility of SalL and NovO to operate in a one-pot process. 
The model substrate 1b was used with an excess of ClDA (5, 2 
eq.) and Met (6, 50 eq.) using an E. coli cell-free extract from the 
overexpression of NovO (Figure 1a; Entry A). Based on the 
previously reported kinetic parameters for SAM formation  
 
 
(a) 
 
(b) 
 
Figure 1. (a) Reaction optimization using substrate 1b. E. coli cell lysates 
were used and % conversion determined by HPLC (area/area%) after 24 h. 
Reagents and conditions: (i) ClDA, Met, BSA, DTT, NovO cell lysate in 50 mM 
phosphate buffer, pH 6.5 resuspended at 10 mL/ g pellet, SalL cell free extract 
in 50 mM phosphate buffer, pH 6.8 resuspended at 5 mL/ g pellet. A: 2 eq. 
ClDA, 50 eq. Met; B: 1 eq. ClDA, 50 eq. Met; C: 2 eq. ClDA, 2 eq. Met; D: 2 
eq. ClDA, 1 eq. Met; E: 2 eq. ClDA, no Met added; F: No ClDA or Met added. 
(b) Reaction optimization using purified enzymes. Reagents and conditions: (i) 
Met, SalL, BSA, 50 mM potassium phosphate buffer pH 6.5, ClDA, 37 °C, 8 
hours. (ii) NovO, 37 °C, 16 hours. A: 2 eq. ClDA, 10 eq. Met, 0.5 PM MTAN 
added with NovO.; B: 2 eq. ClDA, 10 eq. Met; 2 uM SAHH added with NovO; 
C: 1.5 eq. ClDA, 1.5 eq. Met, 0.5 uM MTAN added with NovO; D: 1.1 eq. ClDA, 
1.1 eq. Met, 0.5 uM MTAN added with NovO; E: 1.5 eq. ClDA, 2 eq. Met, 1 
mM DTT and 0.5 uM MTAN added with NovO; F: 1.5 eq. ClDA, no Met added; 
0.5 uM MTAN added with NovO. Optimised conditions highlighted in blue. 
compared to ClDA formation, low levels of chloride present in 
the system were not anticipated to affect conversion levels.[36] 
No other sources of chloride were added to the system. 
This resulted in quantitative conversion of 1b into the 
methylated product 2b in 24 hours. We then optimised the 
reaction conditions, firstly by minimising the number of 
equivalents of Met and ClDA relative to substrate 1b (Figure 1a 
and Table S1). When the number of equivalents of ClDA was 
reduced from 2 to 1.5 eq., a drop off in the formation of 2b was 
observed (Table S1). Quantitative conversion was optimal with 2 
equivalents of Met (Figure 1a, Entry C). Decreasing the amount 
of Met further to 1 eq. reduced the conversion of 1b to 2b to 
77% (Figure 1a, Entry D). However, when the reaction was run 
without the addition of Met, 30% methylation of 1b was observed 
(Figure 1a, Entry E). To determine whether this was due to 
residual SAM or Met present in the reaction mixture, the reaction 
was also run in the absence of ClDA (Figure 1a, Entry F). In 
this case, no conversion to 2b was observed, which was 
indicative of background methylation being caused by residual 
Met present in the cell lysate and cell free extract (Table S3).  
To address this issue, purified enzymes were used (Figure 
1b and Table S2). Additionally, methylthioadenosine 
nucleosidase (MTAN) or SAH hydrolase (SAHH) was added to 
remove SAH from the reaction mixture, which is a known 
inhibitor of many SAM dependent MTs.[18,37,38] Since ClDA 
inhibits both MTAN[39] and SAHH[40],  SAM was pre-formed in 
situ before the addition of NovO and MTAN or SAHH. Initially, 
the reaction was carried out using 2 eq. ClDA and 10 eq. Met 
with either MTAN or SAHH (Figure 1b, Entries A and B). Whilst 
only 68% conversion was achieved with SAHH, nearly 
quantitative methylation of 1b was observed using MTAN as an 
additive. Further optimisation enabled the reduction of the 
number of equivalents of ClDA from 2.0 to 1.5 without loss of 
conversion to 2b when 1 eq. DTT was added.[41] Carrying out the 
reaction in the absence of MTAN decreased the conversion by 
~40%, confirming the role of MTAN decreasing by-product 
inhibition caused by SAH. Indeed, an IC50 value of 9.8 µM for 
ClDA has been reported for MTAN from E. coli, which was used 
in our study.[42] Finally, only 4% methylation was observed when 
the reaction was carried out in the absence of Met, which may 
be due to residual SAM bound in NovO (Figure 1b and Table 
S2).  
With optimised conditions for a one-pot, tandem SAM 
formation C-methylation process in hand, we next explored the 
scalability of the methodology. The tandem process was carried 
out with Met, three isotopically labelled Met analogues and 
ethionine; using 20 mg of 1b, 1c or 3 in each case. To the best 
of our knowledge, this is the first time that a tandem process 
which involved the in situ formation of SAM has been used on 
preparative scale. For the transfer of an unlabelled methyl group, 
crude E. coli cell lysate (NovO) and E. coli cell free extract (SalL) 
was used, whilst purified enzymes were employed for the 
transfer of isotopically labelled and ethyl groups. Moderate 
(65%) to excellent (88-100%) levels of conversion were obtained 
for transfer of CH3, 13CH3, CD3 and 13CD3, with 1c showing 
quantitative conversion and isolated yields 76-91% in all cases 
(Table 1). High levels of conversion (88-97%) were also 
obtained for 1b, although isolated yields were lower due to poor 
solubility of the corresponding products during work-up. 
Alkylation of 3 was also successful on this scale to form 4 in high 
conversions (69-87%) using purified SalL and NovO, whilst 65% 
of 4 was formed using the cell lysate.  
In summary, we have demonstrated a scalable biocatalytic 
platform for a Friedel-Crafts alkylation using SalL for in situ 
cofactor SAM analogue synthesis from inexpensive starting 
materials. Furthermore, to the best of our knowledge this is the 
first example of using SalL for in situ cofactor production in 
tandem with a MT for the site specific C-methylation/alkylation of 
a small molecule. We envisage that our enzymatic platform 
could form the basis of a valuable biocatalytic tool for late-stage, 
regiospecific labelling of small molecules.[33,43±45] 
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Table 1. Preparative [(20 mg starting material [0.07 mmol 1b and 1c; 0.125 
mmol 3)] scale tandem enzymatic alkylation.  
 
 
 
 
 
 
 
R1 
Substrate CH3 13CH3 CD 3 13CD 3 Et 
1b 
97% 
(53%)[a] 
95% 
(76%)  
88% 
(52%) 
90% 
(47%) 
34% 
(18%)[b] 
1c 
100% 
(76%)[a] 
100% 
(90%) 
100% 
(80%) 
100% 
(75%) 
30% 
(27%)[b] 
3 
65% 
(46%)[a] 
94% 
(83%) 
91% 
(68%) 
92% 
(85%) 
7%[b] 
[a] Reaction carried out using NovO cell lysate and SalL cell free extract and 
purified MTAN. [b] 32 hour pre-incubation with SalL. Reagents and conditions: 
(i) SalL (0.5 mol%), BSA (1 mg/mL), DTT (1 eq.), 50 mM potassium phosphate 
buffer pH 6.5, ClDA (5, 1.5 eq.), Met or Met analogue (2 eq.), 37 °C, 7 hours 
(CH3, 13CH3, CD3 and 13CD3) or 32 hours (Et). (ii) NovO (4 mol%), MTAN (0.05 
mol%), 37 °C, 16 hours. Reactions carried out using 20 mg of substrate. 
Yields of isolated products in parentheses. Representative chromatograms for 
each substrate are shown in the Supporting Information. 
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1 Overexpression and purification of SalL, NovO and MTAN 
SalL  
The plasmid pET26b(+)-SalL (codon optimised for E. coli) was transformed into E. Coli BL21 DE3 
competent cells (Invitrogen) for protein expression. Transformants harbouring the plasmids were grown 
at 37 Û&LQ/%PHGLXPVXSSOHPHQWHGZLWKJP/NDQDP\FLQ to provide the seed culture. The seed 
culture was used to innoculate 1L 2YHUQLJKW([SUHVVPHGLD and grown to an optical density (OD) of 
2WKHQLQFXEDWHGIRUDIXUWKHUKRXUVDWÛ&7KHFHOOVZHUHKDUYHVWHGE\FHQWULIXJDWLRQJIRU
20 minutes at 4 °C). To prepare cell free extract for use in the cascade reaction, the cell pellet was 
resuspended in potassium phosphate buffer (50 mM, pH 6.8) at a volume of ~5 mL/ g of cell pellet. The 
cells were lysed by sonication on ice (5 minutes, 9.0 sec on, 10.0 sec off), at 40% amplitude. The 
resulting cell lysate was clarified by centrifugation (20 min, 4000 rpm, 4 °C) and the supernatant stored 
at -80 °C for further use.   
NovO  
The plasmid pET26b(+)-NovO (codon optimised for E. coli) was transformed into E. Coli BL21 DE3 
competent cells (Invitrogen) for protein expression. Transformants harbouring the plasmids were grown 
DWÛ&LQ/%PHGLXPVXSSOHPHQWHGZLWKJP/NDQDP\FLQ to provide the seed culture.  To 950 
mL Magic media in 2.5 L ultra flasks was added 5P/µ&RPSRQHQW%¶ v/v), 1 mL kanamycin (50 
mg/ mL, to a final concentration of 50 µg/ mL) and 20 mL seed culture (2% v/v). The flasks were 
incubated at 30 °C, 200 rpm and grown to an OD600 of ~2 before the temperature was reduced to 18 °C 
and incubated at 200 rpm overnight. The cells were harvested by centrifugation (4400 rpm, 4 °C, 20 
minutes) and stored at -80 °C for further use. 
MTAN 
The plasmids pET21b(+)-MTAN (codon optimised for E. coli) was transformed into E. Coli BL21 
((DE3)) competent cells (Invitrogen) for protein expression. Transformants harbouring the plasmids 
ZHUHJURZQDWÛ&LQ/%PHGLXPVXSSOHPHQWHGZLWKJP/DPSLFLOOLQRYernight to provide 
seed culture. Overnight Express (OE) media containing ampicillin (to a final concentration of 100 µg/ 
mL) was innoculated with seed culture (2% v/v). The flasks were incubated at 30 °C at 200 rpm and 
grown to an OD of ~2 before lowering the temperature to 18 °C and inbating at 200 rpm overnight. The 
cells were harvested by centrifugation (4400 rpm, 4 °C, 20 minutes) and were stored at -80 °C for 
further use.  
Purification of SalL 
Binding Buffer (Buffer A): 50 mM K Phosphate, 20 mM imidazole, 500 mM Na2SO4, pH 7.9. 
Elution Buffer (Buffer B): 50 mM K Phosphate, 500 mM imidazole, 500 mM Na2SO4, pH 7.9. 
The cell pellet harbouring SalL was resuspended in binding buffer (~10 mL/ g) and lysed by sonication 
(5 min, 0.5 s on, 0.5 s off).  The cell lysate was clarified by centrifugation (90 min, 100 000 g, 4 °C) 
and loaded onto a pre-equilibrated HisTRAP HP 5 mL column at a flow rate of 1 mL / min, collecting 
the flow through. The column was washed with 25 mM imidazole until UV absorbance was stable. The 
protein was eluted with a gradient of 0-100% elution buffer over 20 CV to a final concentration of 500 
mM imidazole, collecting 2 mL fractions. Fractions containing MTAN were determined by SDS PAGE 
and  pooled and concentrated to 3 mL. The sample was desalted using a PD-10 column (GE healthcare), 
eluting with 50 mM phosphate buffer, pH 7.5 + 10% glycerol.  
Purification of MTAN 
Binding Buffer: 50 mM potassium phosphate buffer pH 7.5 + 20 mM imidazole. 
Elution buffer: 50 mM potassium phosphate buffer pH 7.5 + 500 mM imidazole. 
The cell pellet harbouring MTAN was resuspended in binding buffer (~10 mL/ g) and lysed on ice by 
sonication (5 min, 0.5 s on, 0.5 s off).  The cell lysate was clarified by centrifugation (90 min, 100 000 g, 
4 °C) and loaded onto a pre-equilibrated HisTRAP HP 1 mL column at a flow rate of 1 mL/ min, 
collecting the flow through. The column was washed with 25 mM imidazole until UV absorbance was 
stable. The protein was eluted with a gradient of 4-50% elution buffer over 20 CV to a final 
concentration of 250 mM imidazole, collecting 2 mL fractions. Fractions containing MTAN were 
determined by SDS PAGE, pooled and concentrated to 3 mL. The sample was desalted using a PD-10 
column (GE healthcare), eluting with 50 mM HEPES, pH 8 +10% glycerol.  
Purification of NovO  
Binding Buffer: 50 mM Tris-HCl, 300 mM NaCl, 20 mM imidazole pH 8.0 
Elution Buffer: 50 mM Tris-HCl, 300 mM NaCl, 500 mM imidazole, pH 8.0 
The cell pellet harbouring NovO was resuspended in binding buffer (~10 mL/ g) and lysed on ice by 
sonication (5 min, 0.5 s on, 0.5 s off, 40% intensity).  The cell lysate was clarified by centrifugation (90 
min, 100 000 g, 4 °C) and loaded onto a pre-equilibrated HisTRAP HP 5 mL column at a flow rate of 
1 mL/ min, collecting the flow through. The column was washed with 25 mM imidazole until UV 
absorbance was stable. The protein was eluted with a linear gradient of  0-100% elution buffer over 20 
CV. Fractions containing NovO or CouO were determined by SDS PAGE and  pooled and concentrated 
to 3 mL. Protein The sample was desalted using a PD-10 column (GE healthcare), eluting with 100 mM 
Tris-HCl, 150 mM NaCl, 40% glycerol, pH 8.  
2 Optimisation of reaction conditions 
 
 
Entry Eq. ClDA Eq. Met % Conversion 
1 5 50 100 
2 2 50 100 
3 1.5 50 95 
4 1 50 72 
5 2 5 100 
6 2 2 100 
7 2 1 77 
8 2 - 30 
9 - - 0 
Table S1. Optimisation of tandem reaction using E. coli cell lysates. % Conversion by area/area% by HPLC reported after 24 
h. Reagents and conditions: (i) ClDA, Met, BSA, DTT, NovO cell lysate in 50 mM phosphate buffer, pH 6.5 at 10 mL/ g 
pellet, SalL cell free extract in 50 mM phosphate buffer, pH 6.8 at 5 mL/ g pellet.  
 
 
 
 
  
 
Entry Eq. ClDA Eq. L-Met Additives Conversion (%) 
1 2 10 MTAN 95 
2 2 10 SAHH 68 
3 2 5 MTAN 100 
4 2 2 MTAN 99 
5 1.5 1.5 MTAN 92 
6 1.5 2 MTAN 98 
7 1.1 1.1 MTAN 66 
8 1.1 1.5 MTAN 75 
9 1.5 2 DTT+MTAN 100 
10 1.5 2 - 61 
11 1.5 0 DTT+MTAN 4 
Table S2. Optimisation of tandem reaction using purified enzymes. % Conversion by area/area% by HPLC reported after 24 h. 
Reagents and conditions: (i) Met, SalL, BSA, 50 mM potassium phosphate buffer pH 6.5, ClDA, 37 °C, 8 hours. (ii) NovO, 
37 °C, 16 hours.  
3 Investigation into removal of residual Met 
A screen of methods to remove Met was carried out (Table S3). In each case the conversion of substrate 
1b to methylated substrate 2b was measured both without and with the addition of 2 eq. Met. The latter 
was carried out as a positive control to determine whether the enzymes retained activity after each 
treatment.  
 
Entry NovO/ CouO SalL  
- Met + Met 
% Conversion NovO % Conversion NovO 
1 Cell lysate CFE 30 - 
2 CFE CFE 29 - 
3 Washed cell lysate Washed CFE 20 70 
4 Filtered CFE Filtered CFE 9 83 
5 Washed cell lysate Purified 16 98 
6 Washed and filtered CFE Purified 25 92 
7 Dialysed CFE Dialysed CFE 0 55 
Table S3. Screening of methods to remove residual Met from tandem reaction system. MTases were diluted at 10 mL/g cell 
pellet, SalL was diluted at 5 mL/g cell pellet. CFE:cell free extract. Filtered CFE: CFEs were filtered twice using an Amicon 
Ultra Centrifugal Filter with a 10 KDa MW limit. Washed CFE: cell pellet was washed twice with 50 mM phosphate buffer 
prior to lysing. Dialysed CFE: CFE dialysed for 16 hours at 4 °C in phosphate buffer using 10 KDa MW limit dialysis tubing. 
Purified: Enzyme purified by HisTRAP affinity chromatography. 
4 Synthesis of ClDA (5) 
(2R,3R,4S,5S)-2-(6-amino-9H-purin-9-yl)-5-(chloromethyl)tetrahydrofuran-3,4-diol (5)1 
 
To an ice cooled suspension of adenosine (1.00 g, 3.74 mmol) in acetonitrile (10 mL) was added 
pyridine (0.61 mL, 7.48 mmol) and thionyl chloride (1.40 mL, 18.7 mmol) was added dropwise over 5 
minutes. The reaction mixture was stirred at 0 ºC for 3 hours before being warmed to 22 ºC and stirred 
for 16 hours. The resulting precipitate was filtered and dissolved in water/ methanol (5:1). Aqueous 
ammonia (25%, 2.00 mL) was added and the reaction mixture stirred at 22 ºC for 30 minutes. The 
solvent was removed under reduced pressure to provide the title compound as a colourless amorphous 
solid (1.05 g, 98%). 1H NMR: G (400 MHz, DMSO-d6) 8.35 (s, 1H, Ar-H), 8.17 (s, 1H, Ar-H), 7.31 (s, 
2H, NH2), 5.95 (d, J=5.7 Hz, 1H, CH), 5.59 (d, J=6.0 Hz, 1H, OH), 5.45 (d, J=5.2 Hz, 1H, OH), 4.77 
(q, J=5.6 Hz, 1H, CH), 4.18-4.32 (m, 1H, CH), 4.03-4.16 (m, 1H, CH), 3.78-4.02 (m, 2H, CH2). 13C 
NMR: G (101 MHz, DMSO-d6) 156.1 (C), 152.7 (CH), 149.4 (C), 139.7 (CH), 119.1 (C), 87.4 (CH), 
83.6 (CH), 72.6 (CH), 71.3 (CH), 44.8 (CH2). Mpt.: 72 °C. (lit. 75-80 °C).2 Ȟ
max 
(neat): 3148, 1648, 
1601 cm-1. m/z: (ES+) 286 (M35Cl + H+, 100%), 288 (M37Cl + H+, 35%). Rf: (EtOAc) 0.20. 
  
5 Synthesis of aminocoumarin substrates 1b and 1c 
Aminocoumarin substrates were synthesised by the route outlined by Gruber et al. (Scheme S2Scheme 
S1).3 
 
Scheme S2. Synthetic route to aminocoumarin substrates 1b and 1c.3 Reagents and conditions: (a) KOH, aq. EtOH, 22 °C. 
(b) Ac2O, 4-dimethylaminopyridine (DMAP), NEt3, THF, 0-22 °C (c) (COCl)2, N,N-dimethylformamide (DMF), PhMe, 
40 °C. (d) MgCl2, NEt3, THF, 4 °C, then S4. (e) aq. NaOH, MeOH, 22 °C. (f) HCl in cyclopentylmether ether (CPME), tert-
butylmethyl ether, MeOH, 22 °C. (g) BzCl, NEt3, EtOAc, 22 °C, then aq. NaOH, MeOH 22 °C. (h) (COCl)2, N,N-
dimethylformamide (DMF), PhMe, 40 °C. (i) NEt3, EtOAc, 22 °C, then aq. NaOH, MeOH 22 °C. 
2-(tert-butoxycarbonylamino)-3-ethoxy-3-oxopropanoic acid (S2)4 
 
 
 
To a solution of diethyl 2-((tert-butoxycarbonyl)amino)malonate (S1) (10.0 mL, 39.2 mmol) in ethanol 
(50 mL) was added solid potassium hydroxide (2.25 g, 40.1 mmol). The suspension was stirred at 22 °C 
for 12 hours before concentrating under reduced pressure. The suspension was redissolved in 1 M 
NaHCO3 (75 mL) and washed with EtOAc (2 x 40 mL). The solution was cooled to 0 ºC, acidified with 
solid KHSO4 to pH 2 and extracted with EtOAc (3 x 40 mL). The combined organic fractions were 
washed with brine (20 mL) and dried over Na2SO4. The solvent was removed under reduced pressure 
to provide the title compound as an amorphous colourless solid (7.66 g, 77%).  
1H NMR: G (400 MHz, DMSO-d6) 7.49 (d, J=7.9 Hz, 1H, NH), 4.73 (d, J=7.9 Hz, 1H, CH), 4.15 (q, 
J=7.0 Hz, 2H, CH2), 1.41 (s, 9H, 3xCH3), 1.21 (t, J=7.0 Hz, 3H, CH3). COOH signal not detected. 13C 
NMR:G (101 MHz, DMSO-d6) 167.8 (CO), 167.2 (CO), 156.3 (CO), 78.9 (C), 61.3 (CH2), 57.6 (CH), 
28.1 (CH3), 13.9 (3xCH3). Mpt.: 84-85 °C (lit.:
 
93-95 °C [diethyl ether/ hexane]).4 Ȟ
max 
(neat): 3264, 
2984, 1756, 1733, 1652 cm-1. m/z: (ES+) 248 (M+H+, 6%), 148 (100%). Rf: (EtOAc) 0.53. 
2,4-Diacetoxybenzoic acid (S4)
5
 
 
To a solution of 2, 4-dihydroxybenzoic acid (10.0 g, 64.9 mmol)  in tetrahydrofuran (100 mL) was 
added triethylamine (31.7 mL, 227 mmol), 4-dimethylaminopyridine (0.793 g, 6.49 mmol) and acetic 
anhydride (30.6 mL, 324 mmol) and the reaction was stirred at 22 ºC for 4 h. The reaction mixture was 
acidified with aqueous 1 M HCl to pH 3 and extracted with EtOAc (3 x 100 mL). The combined organic 
fractions were washed with brine (100 mL) and dried over Na2SO4. The solvent was removed under 
reduced pressure and the resulting solid was recrystallised from EtOAc to provide the title compound 
as a colourless crystalline solid (12.6 g, 82%). 1H NMR: į(400 MHz, DMSO-d6) 13.14 (br. s, 1H, 
COOH), 7.98 (d, J=8.6 Hz, 1H, Ar-H), 7.18 (dd, J1=8.6, J2=2.3 Hz, 1H, Ar-H), 7.09 (d, J=2.3 Hz, 1H, 
Ar-H), 2.29 (s, 3H, CH3), 2.24 (s, 3H, CH3). 13C NMR: į (101 MHz, CDCl3) 169.2 (CO), 168.3 (CO), 
168.2 (CO), 155.3 (C), 152.2 (C), 133.5 (C), 119.5 (CH), 119.3 (CH), 117.5 (CH), 21.2 (CH3), 21.0 
(CH3). Mpt.: 135-137 °C (lit.
 
136-137 °C).
5
 Ȟ
max 
(neat): 2859, 1773, 1680, 1607 cm-1. m/z: (ES+) 261 
(M+Na+, 5%), 179 (100%). Rf: (1:1 EtOAc/ heptane) 0.16.  
2-(chlorocarbonyl)-5-hydroxyphenyl acetate (S5) 
 
To a suspension of 2,4-diacetoxybenzoic acid (S4) (5.00 g, 21.0 mmol) in anhydrous toluene (50 mL) 
under a N2 atmosphere in a flame dried flask at 22 °C was added (COCl)2 (3.67 mL, 42.0 mmol) and 
anhydrous DMF (0.16 mL, 2.10 mmol). The reaction mixture was heated to 40 °C and stirred for 2 
hours. The reaction mixture was concentrated under reduced pressure and the resulting crude residue 
was used in the next stage of the synthesis without purification.  
 
Ethyl 3-(2-acetoxy-4-hydroxyphenyl)-2-((tert-butoxycarbonyl)amino)-3-oxopropanoate (S6) 
 
To an ice-cooled solution of 2-(tert-butoxycarbonylamino)-3-ethoxy-3-oxopropanoic acid (S2) (6.47 g, 
26.2 mmol) in anhydrous tetrahydrofuran (50 mL) under an N2 atmosphere was added triethylamine 
(18.4 mL, 132 mmol) and anhydrous MgCl2 (6.79 g, 71.4 mmol). The resulting slurry was stirred 
vigorously at 4 ºC for 2 hours. A solution of the previously prepared crude acid chloride S5 (theoretical 
amount 1 eq.) in anhydrous tetrahydrofuran (50 mL) was then added and the resulting suspension stirred 
for 4 hours. The reaction mixture was quenched with saturated aqueous ammonium chloride (50 mL) 
and extracted with ethyl acetate (3 x 50 mL). The combined organic fractions were washed with brine 
(50 mL) and dried over Na2SO4. The solvent was removed under reduced pressure to provide a brown 
solid which was used in the next stage of the synthesis without further purification. 
tert-Butyl (4,7-dihydroxy-2-oxo-2H-chromen-3-yl) carbamate (S7)3 
 
To a solution of crude coupling product (S6) (theoretical amount 8.89 g, 21.0 mmol) in methanol (100 
mL) was added aqueous 1 M NaOH (105 mL, 105 mmol) and the reaction mixture was stirred at 22 °C 
for 4 hours. The reaction mixture was acidified with 2 M HCl to pH 3 and extracted with EtOAc (3 x 
100 mL). The combined organic fractions were washed with brine (20 mL), dried over MgSO4 and the 
solvent removed under reduced pressure. The resulting solid was recrystallised from EtOAc to provide 
the title compound as a pale orange crystalline solid (3.57 g, 58% over 3 stages). 1H NMR: į (400 MHz, 
DMSO-d6) 7.79 (br. s, 1H, NH), 7.66 (d, J=8.7 Hz, 1H, Ar-H), 6.79 (dd, J1=8.7, J2=2.2 Hz, 1H, Ar-H), 
6.70 (d, J =2.2 Hz, 1H, Ar-H), 1.44 (s, 9H, 3xCH3). OH signals not detected. 13C NMR: į (101 MHz, 
DMSO-d6) 165.4 (CO), 161.2 (CO), 161.2 (C), 157.9 (C), 154.7 (C), 125.0 (CH), 112.8 (CH), 106.3 
(C), 101.8 (CH), 79.3 (C), 77.3 (C), 28.2 (3xCH3). M.pt.: 208-210 °C. Ȟ
max 
(neat): 3370, 1612, 1575 
cm-1. m/z: (ES+) 294 (M+H+, 9%), 238 (100%). Rf: (1:1 EtOAc/ heptane) 0.38.  
 
 3-Amino-4,7-dihydroxy-2H-chromen-2-one hydrochloride (S8)3 
 
To an ice cooled solution of tert-butyl (4,7-dihydroxy-2-oxo-2H-chromen-3-yl) carbamate (S7) (2.50 
g, 8.52 mmol) in tert-butylmethyl ether (TBME) (50 mL) and methanol (15 mL) was added 3 M HCl 
in cyclopentylmethyl ether (42.6 mL, 128 mmol) and the mixture stirred at 22 °C for 24 hours. The 
solvent was removed under reduced pressure and the residue triturated with TBME (10 mL). The 
suspension was filtered to provide the title compounds as an off-white amorphous solid (1.94 g, 99%). 
1H NMR: G (400 MHz, DMSO-d6) 7.78 (d, J=8.6 Hz, 1H, Ar-H), 6.75 (dd, J1=8.6, J2=2.3 Hz, 1H, Ar-
H), 6.64 (d, J=2.3 Hz, 1H, Ar-H). OH and NH2 signals not detected. 13C NMR: G (101 MHz, DMSO-
d6) 161.4 (CO), 160.2 (C), 159.6 (C), 153.8 (C), 125.7 (C), 112.8 (C), 110.3 (CH), 102.3 (CH), 94.3 
(CH). M.pt.: 240-241 °C. Ȟ
max 
(neat): 3336, 1710 cm-1. m/z: (ES+)  194 (M+, 100%). Rf: (EtOAc) 0.03.  
N-(4,7-Dihydroxy-2-oxo-2H-chromen-3-yl) benzamide (1b)3 
 
To a solution of 3-amino-4,7-dihydroxy-2H-chromen-2-one hydrochloride (S8) (0.50 g, 178 mmol) in 
EtOAc (25 mL) was added benzoyl chloride (1.26 mL, 10.9 mmol) and triethylamine (3.04 mL, 21.8 
mmol). The suspension was stirred at 22 °C for 3 hours before being filtered. The filtrate was 
concentrated under reduced pressure and the residue dissolved in methanol (25 mL). Aqueous 1 M 
NaOH (25 mL, 25.0 mmol) was added and the reaction was stirred at 22 °C for 12 hours before 
acidifying to pH 3 with aqueous 2 M HCl. The reaction mixture was extracted with EtOAc (3 x 50 mL) 
and the combined organic fractions were washed with brine (50 mL) and dried over Na2SO4. The 
solvent was removed under reduced pressure and the crude solid washed with EtOAc (10 mL) and 
filtered to provide the title compound as as a pale yellow amorphous solid (0.43 g, 67%). 1H NMR: į 
(400 MHz, DMSO-d6) 11.82 (br. s, 1H, OH), 10.54 (s, 1H, OH), 9.41 (s, 1H, NH), 8.01 (d, J=7.3 Hz, 
2H, Ar-H), 7.73 (d, J=8.7 Hz, 1H, Ar-H), 7.60 (app. t, J=7.3 Hz, 1H, Ar-H), 7.52 (m,   2H, Ar-H), 6.84 
(dd, J1 =8.7, J2=2.3 Hz, 1H, Ar-H), 6.74 (d, J=2.3 Hz, 1H, Ar-H). 13C NMR: į (101 MHz, DMSO-d6) 
166.5 (CO), 161.4 (CO), 160.8 (C), 160.4 (C), 153.5 (C), 133.9 (C), 131.5 (CH), 128.1 (2xCH) 128.0 
(2xCH), 125.0 (CH), 112.9 (CH), 108.0 (C), 101.9 (CH), 100.1 (C). M.pt.: 283-285 °C (lit.: 283-285 
°C).3 Ȟ
max 
(neat): 3176, 1665, 1625 cm-1. m/z: (ES+) 298 (M+H+, 100%). Rf: (1:1 EtOAc/ heptane) 0.31.  
N-(4,7-dihydroxy-2-oxo-2H-chromen-3-yl)-1H-pyrrole-2-carboxamide (1c) 
 
To a suspension of 1H-pyrrole-2-carboxylic acid (968 mg, 8.71 mmol) in anhydrous toluene (50.0 mL) 
was added oxalyl dichloride (1.525 mL, 17.42 mmol) and N,N-dimethylformamide (0.017 mL, 0.218 
mmol). The reaction was heated to 65 °C and stirred for 1 hour before cooling to 22 °C and 
concentrating under reduced pressure. The residue was redissolved in anhydrous dichloromethane 
(10.00 mL) and added to a solution of 4,7-dihydroxy-2-oxo-2H-chromen-3-aminium chloride (500 mg, 
2.18 mmol) and triethylamine (2.43 mL, 17.4 mmol) in dichloromethane (30.0 mL). The reaction was 
stirred at 22 °C for 1 hour before acidfying to pH 2 with aqueous 2 M HCl and extracting with EtOAc 
(3x30.0 mL). The combined organic fractions were dried over a hydrophobic frit and concentrated under 
reduced pressure. The residue was redissolved in methanol (30.0 mL) and sodium hydroxide (10.0 mL, 
10.0 mmol) was added. The reaction was stirred at 22 °C for 1 hour before concentrating under reduced 
pressure and acidifying to pH 5 using aqueous conc. HCl. The mixture was extracted with EtOAc (3x30 
mL), the combined organic fractions washed with brine (30 mL) and dried over a hydrophobic frit.The 
filtrate was concentrated under reduced pressure and the product triturated from MeCN to provide the 
title compound as an amorphous brown solid (294 mg, 47%). 1H NMR: G (DMSO-d6, 400MHz) 12.00 
(br. s., 1H, OH), 11.66 (br. s., 1H, NH), 10.55 (s, 1H, OH), 9.04 (s, 1H, NH), 7.73 (d, J=8.7 Hz, 1H, 
Ar-H), 6.95-7.08 (m, 2H, Ar-H), 6.85 (dd, J=8.7, 2.3 Hz, 1H, Ar-H), 6.75 (d, J=2.2 Hz, 1H, Ar-H). 13C 
NMR: G (101 MHz, DMSO-d6) 161.3 (C), 160.8 (CO), 159.4 (C), 153.2 (C), 125.4 (CH), 125.0 (C), 
122.4 (CH), 113.0 (CH), 112.3 (CH), 109.0 (CH), 108.1 (C), 101.9 (CH), 100.4 (C). One CO signal not 
detected. Mpt.: decomp. > 290 °C. Ȟ
max 
(neat): 3355, 1679, 1642, 1530, 1134, 739 cm-1. m/z: (ES+) 287 
(M+H+, 37%), 145 (100%). Rf: (1:1 EtOAc/ heptane): 0.31. 
6 General procedure for the one-pot enzymatic cascade alkylation using E. coli 
cell free extract and E. coli cell lysate 
To a 50 mL Falcon tube was added substrate 1b, 1c or 3 (20.0 mg, 0.125 mmol, as a 100 mM solution 
in DMSO), 7 (53.6 mg, 0.188 mmol, as a  100 mM solution in DMSO), L-methionine (0.25 mmol, as a 
500 mM solution in aqueous 250 mM NaOH) and DTT (19.3 mg, 0.125 mmol, as a 100 mM solution 
in potassium phosphate buffer). BSA (to a final concentration of 1 mg/ mL) was added before initiating 
SAM synthesis with SalL cell free extract (15 mL, cell pellet resuspended in 5 mL/ g). The reaction 
was incubated at 35 °C, 750 rpm for 2 hours, before adding NovO cell lysate (35 mL, cell pellet 
resuspended in 10 mL/g) and MTAN (0.5 µM) and incubating the reaction at 35 °C, 750 rpm, for a 
further 16 hours  The reaction mixture was acidified to pH 5 with aqueous conc. HCl and clarified by 
centrifugation (20 min, 4000 rpm, 4 °C). The supernatant was extracted 3 times with EtOAc (3x50 mL), 
each time clarifying the emulsion by centrifugation (10 min, 4000 rpm, 4 °C) and the combined organic 
frations purified by mass-directed automated purifcation to provide the title compounds. 
N-(4,7-dihydroxy-8-methyl-2-oxo-2H-chromen-3-yl)benzamide3 
 
97% Conversion by HPLC. Isolated as a colourless solid (11 mg, 53%). 
1H NMR: G(DMSO-d6, 400 MHz) 11.72 (s, 1H, OH), 10.44 (s, 1H, OH), 9.43 (s, 1H, NH), 8.03 (d, 
J=7.3 Hz, 2H, 2xAr-H), 7.57-7.64 (m, 2H, 2xAr-H), 7.50-7.57 (m, 2H, 2xAr-H), 6.91 (d, J=8.7 Hz, 1H, 
Ar-H), 2.20 (s, 3H, CH3). 13C NMR: G (DMSO-d6, 101 MHz) 166.5 (CO), 160.8 (CO), 160.4 (C), 159.1 
(C), 151.5 (C), 133.9 (C), 131.6 (CH), 128.2 (CH), 128.0 (CH), 121.5 (CH), 111.8 (CH), 110.4 (C), 
107.9 (C), 99.9 (C), 8.1 (CH3). Mpt.: Decomp. > 295 °C. Ȟ
max 
(neat): 3215, 1567, 1534, 1097, 695 cm-
1. m/z: (ES+) 312 (M+H+, 100%). Rf: (EtOAc) 0.28. 
 
N-(4,7-dihydroxy-8-methyl-2-oxo-2H-chromen-3-yl)-1H-pyrrole-2-carboxamide3 
 
100% Conversion by HPLC. Isolated as an amorphous pale yellow solid (16 mg, 76%).  
1H NMR: d (DMSO-d6, 400 MHz) 11.89 (s, 1H, OH), 11.66 (br. s., 1H, NH), 10.41 (s, 1H), 9.03 (s, 
1H), 7.58 (d, J=8.6 Hz, 1H, ), 7.04 (br. s., 1H, Ar-H), 6.96 (br. s., 1H, Ar-H), 6.89 (d, J=8.7 Hz, 1H), 
6.17 (d, J=3.0 Hz, 1H), 2.17 (s, 3H, CH3). 13C NMR: G(DMSO-d6, 101 MHz) 160.8 (C), 160.8 (CO), 
159.5 (C), 159.0 (C), 151.2 (C), 125.4 (C), 122.4 (CH), 121.5 (CH), 112.3 (CH), 111.9 (CH), 110.4 (C), 
109.0 (CH), 108.0 (C), 100.1 (C), 8.1 (CH3). One CO signal not detected. Mpt.: Decomp. >300 °C. 
Ȟ
max 
(neat): 3340, 1584, 1532, 1404, 731 cm-1. m/z: (ES+) 301 (M+H+, 100%). Rf: (1:1 EtOAc/heptane) 
0.33. 
1-methylnaphthalene-2,7-diol3 
 65% Conversion by HPLC. Isolated as a pink solid (10 mg, 46%). 
1H NMR:G(METHANOL-d4, 400 MHz) 7.56 (d, J=8.9 Hz, 1H, Ar-H), 7.43 (d, J=8.9 Hz, 1H, Ar-H), 
7.12 (d, J=2.2 Hz, 1H, Ar-H), 6.87 (d, J=8.8 Hz, 1H, Ar-H), 6.83 (dd, J=8.8, 2.2 Hz, 1H, Ar-H), 2.38 
(s, 3H, CH3). 13C NMR: G (METHANOL-d4, 101 MHz) 156.8 (C), 153.7 (C), 137.3 (C), 131.0 (CH), 
127.9 (CH), 125.3 (C), 115.9 (CH), 115.6 (CH), 106.0 (CH), 10.8 (CH3). One C signal not detected. 
Mpt.: 148.1 °C. Ȟ
max 
(neat): 3221, 1626, 1185, 1098, 822 cm-1. m/z: (ES+) 173 (M-H+, 45%),  347 
(100%). Rf: (1:1 EtOAc/heptane) 0.28. 
7 General procedure for the one-pot enzymatic cascade alkylation using purified 
enzymes 
To a 50 mL Falcon tube was added substrate 1b, 1c or 3 (20.0 mg, 0.125 mmol, as a 100 mM solution 
in DMSO), 7 (53.6 mg, 0.188 mmol, as a  100 mM solution in DMSO), L-methionine (or isotopically 
labeled analogue, purchased from Sigma Aldrich) or L-ethionine (0.25 mmol, as a 500 mM solution in 
aqueous 250 mM NaOH), potassium phosphate buffer (50 mM, pH 6.5, 40 mL) and DTT (19.3 mg, 
0.125 mmol, as a 100 mM solution in potassium phosphate buffer). BSA (to a final concentration of 1 
mg/ mL) was added before initiating SAM or SAM-analogue synthesis with SalL (5 µM). The reaction 
was incubated at 35 °C, 750 rpm for 7 hours (-CH3, 13CH3, 13CD3, CD3 transfer) or 32 hours (Et transfer) 
before adding NovO (40 µM) and MTAN (0.5 µM) and incubating the reaction at 35 °C, 750 rpm, for 
a further 16 hours. The reaction mixture was acidified to pH 5 with aqueous conc. HCl and the solids 
removed by centrifugation (20 min, 4000 rpm, 4 °C). The supernatant was extracted 3 times with EtOAc 
(3x50 mL), each time clarifying the emulsion by centrifugation (10 min, 4000 rpm, 4 °C) and the 
combined organic fractions purified by mass-directed automated purification to provide the title 
compounds. 
 
 
 
N-(4,7-dihydroxy-8-[2H3]-methyl-2-oxo-2H-chromen-3-yl)benzamide 
 88% conversion by HPLC. Product isolated as an amorphous colourless (11 mg, 52%). 
1H NMR:G (DMSO-d6, 400 MHz) 11.72 (s, 1H, OH), 10.43 (s, 1H, OH), 9.42 (s, 1H, NH), 7.98-8.05 
(d, J=3 Hz, 2H, 2xAr-H), 7.55-7.63 (m, 2H, 2xAr-H), 7.48-7.55 (m, 2H, 2xAr-H), 6.89  (d, J=8.7 Hz, 
1H, Ar-H). 13C NMR: G (DMSO-d6, 101 MHz) 166.5 (CO), 160.8 (CO), 160.4 (C), 159.1 (C), 151.5 
(C), 133.9 (C), 131.5 (CH), 128.1 (CH), 128.0 (CH), 121.5 (CH), 111.8 (CH), 110.3 (C), 107.9 (C), 
99.8 (C). Mpt.: Decomp. > 265 °C. Ȟ
max 
(neat): 3214, 1565, 1538 cm-1. HRMS: [C17H112H3O5N]+ 
requires m/z 315.1055, found 315.1047. Rf: (1:1 EtOAc/heptane) 0.39. 
N-(4,7-dihydroxy-8-[2H3]-methyl-2-oxo-2H-chromen-3-yl)-1H-pyrrole-2-carboxamide 
 
100% conversion by HPLC. Product isolated as an amorphous pale yellow solid (17 mg, 80%). 
1H NMR: į (DMSO-d6, 400 MHz): 11.89 (s, 1H, OH), 11.65 (br. s, 1H, NH), 10.42 (s, 1H, OH), 9.03 
(s, 1H, NH), 7.58 (d, J=8.6 Hz, 1H, Ar-H), 7.04 (br. s., 1H, Ar-H), 6.96 (br. s., 1H, Ar-H), 6.89 (d, 
J=8.7 Hz, 1H, Ar-H), 6.17 (d, J=3.3 Hz, 1H, Ar-H). 13C NMR: į (DMSO-d6, 101 MHz) 160.8 (C), 
160.8 (CO), 159.5 (C), 159.0 (C), 151.2 (C), 125.4 (C), 122.4 (CH), 121.5 (CH), 112.3 (CH), 111.9 
(CH), 109.0 (CH), 108.0 (C), 100.1 (C). One CO signal and C2H3 signal not observed. Mpt.: Decomp. 
>300 °C. Ȟ
max 
(neat): 3343, 1587, 1554, 1400, 728 cm-1. HRMS: [C15H102H3O5N2]+ requires  m/z 
304.1007, found  304.0996. Rf: (1:1 EtOAc/heptane) 0.33. 
1-(2H3)-methylnaphthalene-2,7-diol 
 
91% conversion by HPLC. Product isolated as a dark pink solid (15 mg, 68%).  
1H NMR:G(METHANOL-d4, 400 MHz) 7.56 (d, J=8.7 Hz, 1H), 7.43 (d, J=8.7 Hz, 1H), 7.12 (d, 
J=2.3 Hz, 1H), 6.86 (d, J=8.7 Hz, 1H), 6.84 (dd, J=8.7, 2.3 Hz, 1H). 13C NMR:G(METHANOL-d4, 
101 MHz) 156.8 (C), 153.7 (C), 137.4 (C), 131.0 (CH), 127.9 (CH), 125.3 (C), 115.9 (CH), 115.6 (CH)
106.0 (CH). One C and C2H3 signals not detected. Mpt.: Decomp. >170 °C. Ȟ
max 
(neat): 3284, 1634, 
1188, 1027, 823 cm-1. HRMS: [C11H82H3O2]+ requires m/z 178.0942, found 178.0935. Rf: (1:1 
EtOAc/heptane) 0.28. 
 
N-(4,7-dihydroxy-8-[13C2H3]-methyl-2-oxo-2H-chromen-3-yl)benzamide 
 
90% conversion by HPLC. Product isolated as an amorphous colourless solid (10 mg, 47%). 
1H NMR:G(DMSO-d6, 400 MHz) 11.72 (br. s., 1H, OH), 10.43 (s, 1H, OH), 9.42 (s, 1H, NH), 8.01 
(d, J=7.1 Hz, 2H, 2xAr-H), 7.55-7.62 (m, 2H, 2xAr-H), 7.49-7.55 (m, 2H, 2xAr-H), 6.89 (d, J=8.7 Hz, 
1H, Ar-H). 13C NMR: G(DMSO-d6, 101 MHz) 166.5 (CO), 160.8 (CO), 160.4 (C), 159.1 (C), 151.5 
(C), 133.9 (C), 131.5 (CH), 128.1 (CH), 128.0 (CH), 121.5 (CH), 111.8 (C), 110.1 (C), 107.9 (C), 99.8 
(C), 7.3 (spt., J=19.7 Hz, 13C2H3). Mpt.: Decomp. >300 °C. Ȟ
max 
(neat): 3219,1567, 1539, 1139, 695 
cm-1. HRMS: [C1613CH112H3O5N]+ requires m/z 316.1088, found 316.1079. Rf: (1:1 EtOAc/heptane) 
0.39. 
N-(4,7-dihydroxy-8-[13C2H3]-methyl-2-oxo-2H-chromen-3-yl)-1H-pyrrole-2-carboxamide 
 
100% conversion by HPLC. Product isolated as a colourless amorphous solid (16 mg, 75%). 
1H NMR:G (DMSO-d6, 400 MHz) 11.89 (s, 1H, OH), 11.66 (br. s., 1H, NH), 10.41 (s, 1H, OH), 9.03 
(s, 1H, NH), 7.58 (d, J=8.6 Hz, 1H, Ar-H), 7.04 (br. s., 1H, ar-H), 6.96 (br. s., 1H, Ar-H), 6.89 (d, J=8.6 
Hz, 1H, Ar-H), 6.17 (d, J=3.2 Hz, 1H, Ar-H). 13C NMR: G(DMSO-d6, 101 MHz) 160.8 (C), 160.8 
(CO), 159.5 (C), 159.0 (C), 151.2 (C), 125.4 (C), 122.4 (CH), 121.5 (CH), 112.3 (CH), 111.9 (CH), 
109.0 (CH), 108.0 (C), 100.1 (C), 7.3 (spt., J=19.7 Hz, 13C2H3). One CO signal not observed. Mpt.: 
Decomp. >300 °C. Ȟ
max 
(neat): 3182, 1574, 1551, 1403, 735 cm-1. HRMS: [C1413CH102H3O5N2]+ 
requires m/z  305.1041, found 305.1030. Rf: (1:1 EtOAc/heptane) 0.33. 
 
 
1-(13C2H3)-methylnaphthalene-2,7-diol 
 92% conversion by HPLC. Product isolated as a dark pink solid (19 mg, 85%). 
1H NMR:G (METHANOL-d4, 400 MHz) 11.89 (s, 1H, OH), 11.66 (br. s., 1H, OH), 10.42 (s, 1H, Ar-
H), 9.03 (s, 1H, Ar-H), 7.58 (d, J=8.6 Hz, 1H, Ar-H), 7.04 (br. s., 1H), 6.96 (br. s., 1H), 6.89 (d, 
J=8.7 Hz, 1H), 6.17 ppm (d, J=3.3 Hz, 1H). 13C NMR: G(METHANOL-d4, 101 MHz)156.8 (C), 153.7 
(C), 137.3 (C), 131.0 (CH), 127.9 (CH), 125.3 (d, J=2.5 Hz, C), 115.9 (d, J=1.9 Hz, CH), 115.6 (CH), 
106.0 (d, J=4.0 Hz, CH) , 10.1 (spt., J=19.3 Hz, 13C2H3). One C signal not detected. Mpt.: Decomp. 
>170 °C.  Ȟ
max 
(neat): 3228, 1627 cm-1. HRMS: [C1013CH82H3O2] requires m/z = 179.0975, found 
179.0970. Rf: (1:1 EtOAc/heptane) 0.28. 
N-(4,7-dihydroxy-8-[13C]-methyl-2-oxo-2H-chromen-3-yl)benzamide 
 
95% conversion by HPLC. Product isolated as a dark pink solid (16 mg, 76%). 
1H NMR:G(DMSO-d6, 400 MHz) 11.73 (br. s., 1H, OH), 10.44 (s, 1H, OH), 9.43 (s, 1H, NH), 8.03 
(d, J=7.3 Hz, 2H, 2xAr-H), 7.57-7.65 (m, 2H, 2xAr-H), 7.50-7.57 (m, 2H, 2xAr-H), 6.91 (d, J=8.7 Hz, 
1H, Ar-H), 2.19 (d, J=128.7 Hz, 3H, 13CH3). 13C NMR: G (DMSO-d6, 101 MHz) 166.5 (CO), 160.8 
(CO), 160.4 (C), 159.1 (C), 151.4 (C), 133.9 (C), 131.5 (CH), 128.1 (CH), 128.0 (CH), 121.5 (CH), 
111.8 (CH), 110.6 (C), 107.9 (C), 99.8 (C), 8.1 (13CH3). Mpt.: Decomp. >300 °C. Ȟ
max 
(neat): 3203, 
1565, 1538, 1096, 695 cm-1. HRMS: [C1613CH14NO5]+ requires m/z 313.0867, found 313.0892. Rf: (1:1 
EtOAc/heptane) 0.39. 
N-(4,7-dihydroxy-8-[13C]-methyl-2-oxo-2H-chromen-3-yl)-1H-pyrrole-2-carboxamide 
 
100% conversion by HPLC. Product isolated as an amorphous pale yellow solid (19 mg, 90%). 
1H NMR:G (DMSO-d6, 400 MHz) 11.89 (s, 1H, OH), 11.65 (br. s., 1H, NH), 10.41 (s, 1H, OH), 9.03 
(s, 1H, NH), 7.58 (d, J=8.6 Hz, 1H, Ar-H), 7.04 (br. s., 1H, Ar-H), 6.96 (d, J=1.0 Hz, 1H, Ar-H), 6.89 
(d, J=8.7 Hz, 1H, Ar-H), 6.17 (d, J=3.1 Hz, 1H, Ar-H), 2.17 (d, J=128.7 Hz, 3H, 13CH3).13C NMR: 
G(DMSO-d6, 101 MHz) 160.8 (C), 160.8 (CO), 159.5 (C), 159.0 (C), 151.2 (C), 125.4 (C), 122.4 (CH), 
121.5 (CH), 112.3 (CH), 111.9 (CH), 109.0 (CH), 108.1 (C), 100.1 (C), 8.1 (13CH3). One CO signal not 
observed. Mpt.: Decomp. > 300 °C. Ȟ
max 
(neat): 3343, 1587, 1555, 1525, 1401, 729 cm-1. HRMS:. 
[C1413CH13N2O5]+ requires m/z 302.0853, found 302.0840. Rf: (1:1 EtOAc/heptane) 0.33. 
1-(13C)-methylnaphthalene-2,7-diol 
 
94% conversion by HPLC. Product isolated as a dark pink solid (18 mg, 83%). 
1H NMR:G (METHANOL-d4, 400 MHz) 7.56 (d, J=8.7 Hz, 1H), 7.43 (d, J=8.9 Hz, 1H), 7.13 (d, 
J=2.3 Hz, 1H), 6.85 (d, J=8.9 Hz, 1H), 6.83 (dd, J=8.7, 2.3 Hz, 1H), 2.38 (d, J=126.6 Hz, 3H, CH3). 
13C NMR:G (METHANOL-d4, 101 MHz) 156.8 (C), 153.6 (C), 137.3 (C), 131.0 (CH), 127.9 (CH), 
125.3 (d, J=2.5 Hz, C), 115.9 (d, J=1.9 Hz, CH), 115.6 (CH), 106.0 ([d, J=4.0 Hz, C] C), 10.8 (13CH3). 
One C signal not detected. Mpt.: Decomp. >170 °C. Ȟ
max 
(neat): 3284, 1634, 1185, 1068, 833 cm-1. 
HRMS: [C1013CH11O2]+ requires m/z 175.0754, found 175.0704. Rf: (1:1 EtOAc/heptane) 0.28. 
N-(8-ethyl-4,7-dihydroxy-2-oxo-2H-chromen-3-yl)benzamide 
 
34% conversion by HPLC. Product isolated as an amorphous colourless solid (4 mg, 18%). 
1H NMR:G(DMSO-d6, 400 MHz) 11.72 (br. s., 1H, OH), 10.43 (s, 1H, OH), 9.41 (s, 1H, NH), 8.01 
(d, J=7.1 Hz, 2H, 2xAr-H), 7.56-7.66 (m, 2H, 2xAr-H), 7.47-7.56 (m, 2H, 2xAr-H), 6.90 (d,J=8.7 Hz, 
1H, Ar-H), 2.74 (q, J=7.3 Hz, 2H, CH2), 1.12 (t, J=7.4 Hz, 3H, CH3). 13C NMR: G(DMSO-d6, 101 
MHz) 166.6 (CO), 160.9 (CO), 160.5 (C), 158.8 (C), 151.1 (C), 133.9 (C), 131.5 (CH), 128.1 (CH), 
128.0 (CH), 121.8 (CH), 116.6 (C), 112.1 (CH), 108.0 (C) , 99.9 (C), 15.8 (CH2), 13.5 (CH3). Mpt.: 
Decomp. >265 °C. Ȟ
max 
(neat): 3331, 1668, 1571, 1543, 1103, 703 cm-1. HRMS: [C18H16NO]+ requires 
m/z 326.1023, found 326.1012. Rf: (1:1 EtOAc/heptane) 0.45. 
N-(8-ethyl-4,7-dihydroxy-2-oxo-2H-chromen-3-yl)-1H-pyrrole-2-carboxamide 
 30% conversion by HPLC. Product isolated as an amorphous pale yellow solid (6 mg, 27%). 
1H NMR:G(DMSO-d6, 400 MHz) 11.88 (s, 1H, OH), 11.65 (br. s., 1H, NH), 10.40 (s, 1H, OH), 9.02 
(s, 1H, NH), 7.58 (d, J=8.6 Hz, 1H, Ar-H), 7.04 (br. s., 1H, Ar-H), 6.96 (br. s., 1H, Ar-H), 6.89 (d, 
J=8.7 Hz, 1H, Ar-H), 6.17 (d, J=3.2 Hz, 1H, Ar-H), 2.73 (q, J=7.4 Hz, 2H, CH2), 1.11 (t, J=7.4 Hz, 3H, 
CH3). 13C NMR: G (DMSO-d6, 101 MHz) 160.9 (C), 160.8 (CO), 159.6 (C), 158.7 (C), 150.9 (C), 
125.4 (C), 122.4 (CH), 121.7 (CH), 116.5 (C), 112.3 (CH), 112.1 (CH), 109.0 (CH), 100.1 (C), 15.8 
(CH2), 13.5 (CH3). One CO signal not observed. Mpt.: Decomp. > 260 °C. Ȟ
max 
(neat): 3354, 1576, 
1555, 1405, 736 cm-1. HRMS: [C16H15N2O5]+ requires m/z 315.0976, found 315.0965.  Rf: (1:1 
EtOAc:heptane) 0.42 . 
 
 
  
8 Representative HPLC chromatograms for calculation of % conversion 
Percentage (%) conversion was calculated from the ratio of starting material to product after 24 hours 
with a detection wavelength of 320 nm (aminocoumarin substrates 1b and 1c) or 220 nm (2, 7-
dihydroxynaphthalene 3). For each substrate, a representative chromatogram is shown for the transfer 
of 13CD3 and Et groups with the peaks for starting material and product labelled in each case. 
 
13CD3 transfer to 1b 
 
 
 
 
 
 
 
 
 
 
 
13CD3 transfer to 1c 
 
 
 
 
 
 
 
 
 
 
 
 
 
13CD3 transfer to 3 
 
 
 
 
 
 
 
 
 
 
 
 
Ethylation of 1b 
 
 
 
 
 
 
 
 
 
 
Ethylation of 1c 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ethylation of 3 
 
 
 
9 NMR spectra of novel compounds 
N-(4,7-dihydroxy-8-[2H3]-methyl-2-oxo-2H-chromen-3-yl)benzamide 
 
 
   
N-(4,7-dihydroxy-8-[2H3]-methyl-2-oxo-2H-chromen-3-yl)-1H-pyrrole-2-carboxamide 
 
 
   
1-(2H3)-methylnaphthalene-2,7-diol 
 
 
 
  
  
N-(4,7-dihydroxy-8-[13C2H3]-methyl-2-oxo-2H-chromen-3-yl)benzamide 
 
 
 
   
N-(4,7-dihydroxy-8-[13C2H3]-methyl-2-oxo-2H-chromen-3-yl)-1H-pyrrole-2-carboxamide 
 
.  
   
1-(13C2H3)-methylnaphthalene-2,7-diol 
 
 
 
 
N-(4,7-dihydroxy-8-[13C]-methyl-2-oxo-2H-chromen-3-yl)benzamide 
 
 
   
N-(4,7-dihydroxy-8-[13C]-methyl-2-oxo-2H-chromen-3-yl)-1H-pyrrole-2-carboxamide 
 
 
 
1-(13C)-methylnaphthalene-2,7-diol 
 
 
   
 N-(8-ethyl-4,7-dihydroxy-2-oxo-2H-chromen-3-yl)benzamide 
 
 
   
N-(8-ethyl-4,7-dihydroxy-2-oxo-2H-chromen-3-yl)-1H-pyrrole-2-carboxamide 
 
 
 
